Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,978 matching trials from the live ClinicalTrials.gov search.
Filters: San Diego, California Clear all
Completed No phase listed Observational

User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity

NCT01036646
View directory record Official record
Conditions
Oral Anticoagulation
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Loma Linda, California • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 29, 2026, 2:46 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

NCT03937141
View directory record Official record
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
ADU-S100
Drug
Lead sponsor
Chinook Therapeutics, Inc. (formerly Aduro)
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

NCT04129931
View directory record Official record
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

NCT04181723
View directory record Official record
Conditions
Rett Syndrome
Interventions
Trofinetide, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 20 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

NCT00149396
View directory record Official record
Conditions
Colorectal Cancer, Liver Neoplasms
Interventions
NV1020
Drug
Lead sponsor
MediGene
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 29, 2026, 2:46 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466
View directory record Official record
Conditions
Select Advanced Solid Tumors
Interventions
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 29, 2026, 2:46 AM EDT
Terminated Phase 3 Interventional Results available

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

NCT03614156
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 29, 2026, 2:46 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

NCT03348631
View directory record Official record
Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
581
States / cities
Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

NCT00613080
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
119
States / cities
Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 29, 2026, 2:46 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

NCT00496002
View directory record Official record
Conditions
Chronic Hepatitis, Hepatitis B
Interventions
Clevudine, Adefovir
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Anaheim, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Oct 29, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753
View directory record Official record
Conditions
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Interventions
Placebo Matching Mitapivat, Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

NCT03640286
View directory record Official record
Conditions
Obesity
Interventions
VeSTAL
Device
Lead sponsor
Neurovalens Ltd.
Industry
Eligibility
22 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
La Jolla, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 29, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional

Interpersonal Brain Function in Opioid Use

NCT07386769
View directory record Official record
Conditions
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Interventions
Meditation, Psychoeducation
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 29, 2026, 2:46 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682
View directory record Official record
Conditions
Steatohepatitis
Interventions
Ontamalimab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Support, Health, and Fibromyalgia

NCT00000423
View directory record Official record
Conditions
Fibromyalgia, Quality of Life
Interventions
Social support group, Social support and education group
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
21 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Physical Therapy in Women With Interstitial Cystitis

NCT00733603
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
Global Therapeutic Massages (GTM), Myofascial Tissue Manipulation (MTM)
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 29, 2026, 2:46 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01769196
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab, Simtuzumab placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
45 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions
cisplatin, fluoxetine, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
42
States / cities
Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 29, 2026, 2:46 AM EDT
Terminated Not applicable Interventional Results available

Intercostal Cryoneurolysis Following Traumatic Rib Fractures

NCT03917823
View directory record Official record
Conditions
Rib Fractures
Interventions
Cryoneurolysis, Sham comparator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum

NCT06159582
View directory record Official record
Conditions
Pre-Exposure Prophylaxis (PrEP)
Interventions
eSTEP, Usual Care
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 29, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

NCT01092182
View directory record Official record
Conditions
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
Interventions
EPOCH-R, EPOCH-RR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 29, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid (TCS)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 2:46 AM EDT